Morgan Stanley again adjusts its Fed forecast, now sees 4 cuts in 2026
Joseph P Lyssikatos, Chief Scientific Officer of Enliven Therapeutics, Inc. (NASDAQ:ELVN), a $1.31 billion market cap biotechnology company, sold a total of 12,500 shares of common stock on July 21, 2025, according to a Form 4 filing with the Securities and Exchange Commission. According to InvestingPro data, the stock has shown strong momentum recently, trading at $22.35, near its 52-week range of $13.30-$30.03.
The sales were executed in multiple trades with prices ranging from $21.81 to $23.025, resulting in a total value of $278645. Specifically, 11,924 shares were sold at a weighted average price of $22.2625, and 576 shares were sold at a weighted average price of $22.8954. Analysts maintain a strong buy consensus on the stock, with price targets ranging from $33 to $52.
The shares are held by The Lyssikatos Revocable Trust 12/15/2011, for which Lyssikatos serves as trustee. Following the transactions, Lyssikatos indirectly owns 952688 shares of Enliven Therapeutics. The sales were conducted under a Rule 10b5-1 trading plan adopted on November 15, 2024. For comprehensive insider trading analysis and additional financial insights, including 6 more exclusive ProTips, visit InvestingPro.
In other recent news, Enliven Therapeutics has made several notable announcements. The company has priced its $200 million public offering, consisting of 8,394,737 shares of common stock at $19.66 per share, along with pre-funded warrants to purchase up to 1,780,263 shares. This offering is part of Enliven Therapeutics’ broader strategy to raise capital, with an additional option for underwriters to purchase up to $30 million more in common stock. On the research front, H.C. Wainwright raised its price target for Enliven Therapeutics to $48, maintaining a Buy rating following updated results from the Phase 1a/1b ENABLE trial for their drug ELVN-001. TD Cowen also reiterated its Buy rating, emphasizing the drug’s strong market potential and positive data. Goldman Sachs initiated coverage with a Buy rating and a $37 price target, citing favorable Phase 1 data for the same treatment. These developments highlight the growing interest and confidence in Enliven Therapeutics’ lead drug candidate for chronic myeloid leukemia.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.